203 related articles for article (PubMed ID: 16797686)
21. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
Havrilesky LJ; Cragun JM; Calingaert B; Alvarez Secord A; Valea FA; Clarke-Pearson DL; Berchuck A; Soper JT
Gynecol Oncol; 2007 Feb; 104(2):401-5. PubMed ID: 17014898
[TBL] [Abstract][Full Text] [Related]
22. Participation of the general gynecologist in surgical staging of endometrial cancer: analysis of cost and perioperative outcomes.
Hoekstra A; Singh DK; Garb M; Arekapudi S; Rademaker A; Lurain JR
Gynecol Oncol; 2006 Dec; 103(3):897-901. PubMed ID: 16814370
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the outcome benefit conferred by intensive surveillance strategies in women with early-stage endometrial cancer.
Kiran G; Kesterson JP; Ozerkan K; Kanis M; Groman A; Lele S
Eur J Gynaecol Oncol; 2013; 34(6):522-6. PubMed ID: 24601043
[TBL] [Abstract][Full Text] [Related]
24. A review of post-trachelectomy isthmic and vaginal smear cytology.
Singh N; Titmuss E; Chin Aleong J; Sheaff MT; Curran G; Jacobs IJ; Shepherd JH
Cytopathology; 2004 Apr; 15(2):97-103. PubMed ID: 15056170
[TBL] [Abstract][Full Text] [Related]
25. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging.
Meyers MO; Yeh JJ; Frank J; Long P; Deal AM; Amos KD; Ollila DW
Ann Surg Oncol; 2009 Apr; 16(4):941-7. PubMed ID: 19101766
[TBL] [Abstract][Full Text] [Related]
26. Routine use of endometrial cytology in clinical practice.
Bistoletti P; Hjerpe A
Acta Cytol; 1993; 37(6):867-70. PubMed ID: 8249503
[TBL] [Abstract][Full Text] [Related]
27. An evaluation of routine follow-up of patients treated for endometrial carcinoma.
Shumsky AG; Stuart GC; Brasher PM; Nation JG; Robertson DI; Sangkarat S
Gynecol Oncol; 1994 Nov; 55(2):229-33. PubMed ID: 7959289
[TBL] [Abstract][Full Text] [Related]
28. What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?
Abu-Rustum NR; Chi DS; Leitao M; Oke EA; Hensley ML; Alektiar KM; Barakat RR
Gynecol Oncol; 2008 Oct; 111(1):46-8. PubMed ID: 18657853
[TBL] [Abstract][Full Text] [Related]
29. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
Modesitt SC; Tian C; Kryscio R; Thigpen JT; Randall ME; Gallion HH; Fleming GF;
Gynecol Oncol; 2007 Apr; 105(1):59-65. PubMed ID: 17150247
[TBL] [Abstract][Full Text] [Related]
30. Patterns and utility of routine surveillance in high grade endometrial cancer.
Hunn J; Tenney ME; Tergas AI; Bishop EA; Moore K; Watkin W; Kirschner C; Hurteau J; Rodriguez GC; Lengyel E; Lee NK; Yamada SD
Gynecol Oncol; 2015 Jun; 137(3):485-9. PubMed ID: 25838164
[TBL] [Abstract][Full Text] [Related]
31. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
[TBL] [Abstract][Full Text] [Related]
32. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data.
Lamerato L; Havstad S; Gandhi S; Jones D; Nathanson D
Cancer; 2006 May; 106(9):1875-82. PubMed ID: 16572409
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
34. Recurrent endometrial cancer: a retrospective study.
van Wijk FH; Huikeshoven FJ; Abdulkadir L; Ewing PC; Burger CW
Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):114-20. PubMed ID: 16460871
[TBL] [Abstract][Full Text] [Related]
35. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
36. Patient-initiated follow-up after treatment for low risk endometrial cancer: a prospective audit of outcomes and cost benefits.
Coleridge S; Morrison J
Int J Gynecol Cancer; 2020 Aug; 30(8):1177-1182. PubMed ID: 32376734
[TBL] [Abstract][Full Text] [Related]
37. Practice patterns of SGO members for stage IIIA endometrial cancer.
Lee CM; Slomovitz BM; Greer M; Sharma S; Gregurich MA; Burke T; Lu KH; Ramondetta LM
Gynecol Oncol; 2005 Jul; 98(1):77-83. PubMed ID: 15907988
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma.
Cohn DE; Huh WK; Fowler JM; Straughn JM
Obstet Gynecol; 2007 Jun; 109(6):1388-95. PubMed ID: 17540812
[TBL] [Abstract][Full Text] [Related]
39. Which patients with colorectal cancer are followed up by general practitioners? A population-based study.
Mahboubi A; Lejeune C; Coriat R; Binquet C; Bouvier AM; Béjean S; Bedenne L; Bonithon-Kopp C
Eur J Cancer Prev; 2007 Dec; 16(6):535-41. PubMed ID: 18090126
[TBL] [Abstract][Full Text] [Related]
40. Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.
Havrilesky LJ; Secord AA; O'Malley DM; Broadwater G; Bae-Jump V; Cohn DE; Gehrig PA
Gynecol Oncol; 2009 Aug; 114(2):279-83. PubMed ID: 19446319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
